Yourgene Health PLC American Society of Human Genetics Annual Meeting
October 15 2019 - 1:01AM
RNS Non-Regulatory
TIDMYGEN
Yourgene Health PLC
15 October 2019
Yourgene Health plc
("Yourgene" or the "Group")
American Society of Human Genetics Annual Meeting attendance
Manchester, UK - 15 October 2019: Yourgene (AIM: YGEN), a
leading international molecular diagnostics group, announces that
it will be exhibiting at the American Society of Human Genetics
("ASHG") Annual Meeting in Houston, Texas which runs from Tuesday
15 October to Saturday 19 October 2019 (Booth no. 101).
The ASHG Annual Meeting is the first time the Company has taken
an exhibition stand since incorporating a US entity and announcing
that during August 2019 Yourgene secured its first customer
revenues from the USA. The Annual event attracts over 9,000
visitors and brings together researchers, academics, clinicians,
laboratory practice professionals, genetic counsellors, nurses, and
others with a special interest in the field of human genetics.
For more information: https://www.ashg.org/2019meeting/
The Company will be showcasing its portfolio of products and
technologies and raising brand awareness of Yourgene Health as an
international leader in molecular diagnostics. Attending the ASHG
Annual Meeting allows the Company to meet with key suppliers and
partners to enhance commercial and technical relationships, and to
explore potential partnerships and collaborations to broaden the
Company's offering across reproductive health and oncology.
Yourgene Health plc Tel: +44 (0)161 667 1053
Lyn Rees, Chief Executive Officer investors@yourgene-health.com
Barry Hextall, Chief Financial Officer
Joanne Cross, Director of Marketing
Stifel Nicolaus Europe Limited (Sole Tel: +44 (0)20 7710 7600
Corporate Broker)
Nicholas Moore / Matthew Blawat / Ben
Maddison
Walbrook PR Ltd (Media and Investor Tel: +44 (0)20 7933 8780 or yourgene@walbrookpr.com
Relations) Mob: 07980 541 893 / 07584 391 303
Paul McManus / Lianne Cawthorne / 07876 741 001
/ Anna Dunphy
About Yourgene Health
Yourgene Health is an international molecular diagnostics group
which develops and commercialises genetic products and services.
The group works in partnership with global leaders in DNA
technology to advance diagnostic science.
Yourgene develops and commercialises simple and accurate
molecular diagnostic solutions, primarily for reproductive health.
The Group's products include non-invasive prenatal tests (NIPT) for
Down's Syndrome and other genetic disorders, Cystic Fibrosis
screening tests, invasive rapid aneuploidy tests, male infertility
tests and genetic disease tests. Yourgene's commercial footprint is
already established in the UK, Europe, the Middle East, Africa and
Asia.
Our product development, research service and commercial
capabilities extend across the lifecycle of genetic test
development including regulatory submissions. Through our technical
expertise and partnerships, Yourgene Health is also extending its
genetic testing offering into oncology.
Yourgene Health is headquartered in Manchester, UK with offices
in Taipei and Singapore, and is listed on the London Stock
Exchange's AIM market under the ticker "YGEN". For more
information, visit www.yourgene-health.com and follow us on twitter
@Yourgene_Health.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRAEASELFFXNFFF
(END) Dow Jones Newswires
October 15, 2019 02:01 ET (06:01 GMT)
Premaitha (LSE:NIPT)
Historical Stock Chart
From Jun 2024 to Jul 2024
Premaitha (LSE:NIPT)
Historical Stock Chart
From Jul 2023 to Jul 2024